Pavmed Series Z Stock Fundamentals
| PAVMZ Stock | USD 0.01 0.00 0.00% |
PAVmed Series Z fundamentals help investors to digest information that contributes to PAVmed Series' financial success or failures. It also enables traders to predict the movement of PAVmed Stock. The fundamental analysis module provides a way to measure PAVmed Series' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PAVmed Series stock.
At this time, PAVmed Series' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 74.8 M in 2024, whereas Interest Expense is likely to drop slightly above 559.5 K in 2024. PAVmed | Select Account or Indicator |
PAVmed Series Z Company Return On Equity Analysis
PAVmed Series' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current PAVmed Series Return On Equity | -13.58 |
Most of PAVmed Series' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PAVmed Series Z is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
PAVmed Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, PAVmed Series Z has a Return On Equity of -13.5806. This is much lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
PAVmed Series Z Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PAVmed Series's current stock value. Our valuation model uses many indicators to compare PAVmed Series value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PAVmed Series competition to find correlations between indicators driving PAVmed Series's intrinsic value. More Info.PAVmed Series Z is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, PAVmed Series' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PAVmed Series' earnings, one of the primary drivers of an investment's value.PAVmed Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PAVmed Series' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PAVmed Series could also be used in its relative valuation, which is a method of valuing PAVmed Series by comparing valuation metrics of similar companies.PAVmed Series is currently under evaluation in return on equity category among its peers.
PAVmed Series Current Valuation Drivers
We derive many important indicators used in calculating different scores of PAVmed Series from analyzing PAVmed Series' financial statements. These drivers represent accounts that assess PAVmed Series' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PAVmed Series' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 30.8M | 21.4M | 100.6M | 42.8M | 29.8M | 57.7M | |
| Enterprise Value | 31.3M | 21.1M | 98.3M | 39.6M | 58.9M | 62.0M |
PAVmed Fundamentals
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (13.98) % | ||||
| Number Of Shares Shorted | 73.53 K | ||||
| Revenue | 2.45 M | ||||
| EBITDA | (75.74 M) | ||||
| Net Income | (64.17 M) | ||||
| Total Debt | 48.73 M | ||||
| Book Value Per Share | (6.62) X | ||||
| Cash Flow From Operations | (52.04 M) | ||||
| Number Of Employees | 107 | ||||
| Beta | 0.69 | ||||
| Total Asset | 33.12 M | ||||
| Retained Earnings | (294.43 M) | ||||
| Working Capital | (29.68 M) | ||||
| Net Asset | 33.12 M |
About PAVmed Series Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PAVmed Series Z's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PAVmed Series using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PAVmed Series Z based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.7 M | 3 M | |
| Total Revenue | 2.5 M | 1.5 M | |
| Cost Of Revenue | 6.4 M | 6.7 M | |
| Stock Based Compensation To Revenue | 4.54 | 4.32 | |
| Sales General And Administrative To Revenue | 12.62 | 11.99 | |
| Research And Ddevelopement To Revenue | 5.82 | 5.53 | |
| Capex To Revenue | 0.10 | 0.09 | |
| Revenue Per Share | 0.34 | 0.36 | |
| Ebit Per Revenue | (28.06) | (29.46) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.